Antibe Therapeutics Inc (CVE:ATE) (OTCMKTS:ATBPF) updated shareholders Thursday on the progress of its study on its lead drug ATB-346, a novel painkiller being developed as an alternative to currently available opiods. The Toronto-based company’s ongoing Phase 2B study is looking at the effectiveness of the drug in reducing osteoarthritis pain in 360 patients. The biotech company is now running the largest number of sites for any clinical trial conducted in Canada after activating an additional five sites recently, bringing the total number of clinical sites to 40.
EuroLife Brands Inc (CSE:EURO) (OTCMKTS:EURPF), the cannabis-focused group, is looking to build on its success in Germany to break into the thriving Swiss market. "We continue to leverage our network of contacts throughout Europe and look to Switzerland with great interest," said Derek Ivany, chairman of the EuroLife Brands advisory board.
Medgold Resources Corp (CVE:MED) (OTCMKTS:MGLDF) unveiled encouraging metallurgical results from its Tlamino project in Serbia Thursday as it also reported final drill assays from the Karamanica prospect at the property. Flotation tests were carried out on two composite samples formed of 50.39 kg of material from the 2018 drilling at the Barje prospect, said the Vancouver-based firm.
NexTech AR Solutions Corp (OTCMKTS:NEXCF) (CSE:NTAR), the technology group, announced a major milestone Thursday - that its augmented reality (3D/AR) solution can be integrated seamlessly with leading eCommerce platform Magento 2.0. It means 250,000 eCommerce sites can now sign up for NexTech’s 3D/AR-enabled products, the Toronto-based company said in a statement.
Group Eleven Resources Corp (CVE:ZNG) (OTCMKTS:GRLVF) is saying goodbye to its co-founder and exploration vice president John Barry, the explorer announced Thursday. Barry, who served as the Vancouver-based company’s chair before its IPO in December 2017, is also resigning as director of Group Eleven’s various Irish subsidiaries, according to the company.
Haywood Securities has started coverage of Metalla Royalty & Streaming Ltd (CVE:MTA) (OTCMKTS:MTAFF) with a 'Buy' rating and C$2 price target against a current target price of C$1.28, according to market sources. In a note to clients, Haywood analyst Kerry Smith described the growing royalty firm as "an active player that will continue to grow in a niche market".